ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2633 • 2018 ACR/ARHP Annual Meeting

    Disease Activity, Organ Damage and Patient-Reported Outcome Measures in Swedish Patients with Recent-Onset SLE

    Rebecca Heijke1, Mathilda Björk1, Martina Frodlund1, Laura McDonald2, Evo Alemao3 and Christopher Sjöwall1, 1Linköping University, Linköping, Sweden, 2Bristol-Myers Squibb, Uxbridge, United Kingdom, 3Bristol-Myers Squibb, Princeton, NJ

    Background/Purpose: Patient (pt)-reported outcome measures (PROMs) are important to inform shared decision-making between pts with SLE and physicians.1 Established measures of disease activity and organ…
  • Abstract Number: 2634 • 2018 ACR/ARHP Annual Meeting

    The Risk of Hydroxychloroquine Retinopathy in an SLE Cohort: Screening and Prevention in Clinical Practice

    Caroline Siegel1, Jennifer M. Grossman2, John Fitzgerald3, Bevra H Hahn4, Sarah Chen5, Lori Sahakian4, Eloise Olmos2, Michael B. Gorin6 and Maureen A. McMahon2, 1Department of Internal Medicine, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 3Medicine-Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 4UCLA David Geffen School of Medicine, Los Angeles, CA, 5Brigham and Women's Hospital, Boston, MA, 6Department of Ophthalmology, UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for SLE because of its highly favorable risk-benefit ratio. Drug-induced retinopathy is one of very few serious…
  • Abstract Number: 2635 • 2018 ACR/ARHP Annual Meeting

    Combined Panel of Nine Tests Has the Greatest Sensitivity but the Lowest Specificity to Detect Antiphospholipid Antibody Syndrome in Patients with Systemic Lupus Erythematosus

    Saika Sharmeen1, Katalin Banki2 and Andras Perl3, 1Medicine, State University of New York Upstate Medical University, Syracuse, NY, 2Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, 3Medicine, SUNY Upstate Medical University, Syracuse, NY

    Background/Purpose: Antiphospholipid antibody syndrome (APS) is an autoimmune hypercoagulable state caused by antiphospholipid antibodies (aPL) which represent a diagnostic criterion and underlie significant comorbidities in…
  • Abstract Number: 2636 • 2018 ACR/ARHP Annual Meeting

    Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database

    Osman Bhatty1, Sarah Aurit2, Rouhin Sen3, Joseph Nahas4 and Sunil Jagadesh5, 1Department of Medicine, CHI Creighton University Medical Center, New Hempstead, NY, 2Department of Surgery, CHI Creighton University Medical Center, Omaha, NE, 3Internal Medicine, CHI Creighton University Medical Center, Omaha, NE, 4Department of Rheumatology, CHI Creighton University Medical Center, Omaha, NE, 5Department of Nephrology, CHI Creighton University Medical Center, Omaha, NE

    Background/Purpose: Twenty to sixty percent of patients with systemic lupus erythematous (SLE) can progress to lupus nephritis (LN) and those that do can develop end…
  • Abstract Number: 2637 • 2018 ACR/ARHP Annual Meeting

    Hydroxychloroquine Improves Disease Activity and Allows Reduction of Corticosteroid Dose Regardless of Background Treatment in Japanese Patients with Systemic Lupus Erythematosus

    Hironari Hanaoka, Harunobu Iida, Tomofumi Kiyokawa, Yukiko Takakuwa and Kimito Kawahata, Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan

    Background/Purpose: Hydroxychloroquine (HCQ) was not approved in Japan until 2015 and its therapeutic potential remains poorly understood in the population. In this study, we evaluated…
  • Abstract Number: 2638 • 2018 ACR/ARHP Annual Meeting

    Tacrolimus Use in Hispanic Patients with Refractory Lupus Nephritis

    Phillip Aleksiejuk1 and Elizabeth Ortiz2, 1Rheumatology, University of Southern California, Los Angeles, CA, 2Department of Rheumatology, University of Southern California, Los Angeles, CA

    Background/Purpose: Lupus nephritis is one of the most common and severe manifestations of patients with SLE. Studies assessing the use of Tacrolimus (TAC) in lupus…
  • Abstract Number: 2639 • 2018 ACR/ARHP Annual Meeting

    Bone Mineral Density Is Not Associated with Osteoporotic Fractures in Premenopausal Women and Men < 50 Years Old with Systemic Lupus Erythematosus

    Tracy Driver1, Maureen A. McMahon2, Betty Tsao3 and Jennifer M. Grossman4, 1Medicine, Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2UCLA David Geffen School of Medicine, Los Angeles, CA, 3Medical University of South Carolina, Charleston, SC, 4Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

    Background/Purpose: Osteoporosis is common in patients with systemic lupus erythematosus (SLE). Guidelines for the treatment and prevention of glucocorticoid induced osteoporosis (GIOP) are detailed for…
  • Abstract Number: 2640 • 2018 ACR/ARHP Annual Meeting

    Hematologic Activity in Systemic Lupus Erythematosus: Is Splenectomy Our Best Choice?

    María Fernanda Zavala-Miranda1, Samuel Govea-Peláez2, Ricardo Vázquez-Rodríguez2, Roberto Reyna2, Sandra Morales2, Diana Gómez-Martín3, Jorge Alcocer-Varela3, Javier Merayo-Chalico2 and Ana Barrera-Vargas2, 1Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 3Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

    Background/Purpose: Hematologic manifestations are found in up to 30% of SLE patients. Although splenectomy is considered an acceptable therapeutic option for both refractory thrombocytopenia and…
  • Abstract Number: 2641 • 2018 ACR/ARHP Annual Meeting

    Hydroxychloroquine Could Modulate S100 Proteins Expression, Which Reflect the Activity of Lupus Nephritis or Skin Lesion, in Systemic Lupus Erythematosus Patients with Low Disease Activity

    Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Kiyo Ueeda and Hiroaki Dobashi, Internal Medicine Division of Hematology, Rheumatology, and Respiratory Medicine, Kagawa University, Kagawa, Japan

    Background/Purpose: To find the effect of HCQ treatment on expression of S100 proteins which were reported to reflect the activity of SLE including lupus nephritis…
  • Abstract Number: 2642 • 2018 ACR/ARHP Annual Meeting

    Atacicept Dose Rationale for a Phase 3 Study in Patients with High Disease Activity and Auto-Antibody Positive SLE

    Jinshan Shen1, Orestis Papasouliotis2, Eileen Samy1, Philipp Haselmayer3, Peter Chang4, Victor Ona1 and Amy H. Kao1, 1EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, 2Merck Institute for Pharmacometrics, an affiliate of Merck KGaA, Darmstadt, Germany, Lausanne, Switzerland, 3Merck KGaA, Darmstadt, Germany, 4EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA

    Background/Purpose: Atacicept targets the B-cell-stimulators BLyS and APRIL, and is in development for the treatment of patients (pts) with SLE. Here, we integrated non-clinical and…
  • Abstract Number: 2643 • 2018 ACR/ARHP Annual Meeting

    Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus

    Zahi Touma1, Murray Urowitz2, Dafna D Gladman2, Carrie Wagner3, Bei Zhou3, Robert Gordon3, Benjamin Hsu3, Marc Chevrier3 and Shawn Rose3, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Krembil Research Institute, U of Toronto, Toronto, ON, Canada, 3Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: Ustekinumab (UST), a monoclonal antibody that targets the shared p40 subunit of the cytokines IL-12 & IL-23, is being investigated in patients (pts) w/…
  • Abstract Number: 2644 • 2018 ACR/ARHP Annual Meeting

    Identifying Response for the Systemic Lupus Erythematosus Disease Activity Glucocorticoid Index (SLEDAI-2KG)

    Zahi Touma1, Dafna D Gladman2, Jiandong Su1, Nicole Anderson3 and Murray Urowitz2, 1University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a valid index able to measure disease activity while accounting for glucocorticoid (GC)…
  • Abstract Number: 2645 • 2018 ACR/ARHP Annual Meeting

    The Impact of Metformin on Disease Activity in Systemic Lupus Erythematosus

    Cara McLeod1, Gbemisola Olayemi1, Nitasha Bhatia2, Frank Migliore3 and Robert Quinet1, 1Rheumatology, Ochsner Medical Center, New Orleans, LA, 2Ochsner Medical Center, New Orleans, LA, 3Rheumatology, Allegheny Health Network, Pittsburgh, PA

    Background/Purpose: Metformin is a mainstay of therapy for type 2 diabetes mellitus. Newer evidence suggests that metformin may reduce lupus flares. An entity called neutrophil…
  • Abstract Number: 2646 • 2018 ACR/ARHP Annual Meeting

    Disparities in Antimalarial Prescribing for Systemic Lupus Erythematous Nephritis Using a Real-World, Electronic Health Record

    Wenlu Xiong1, J.B. Boone1, Cecilia P. Chung1, Leslie Crofford2 and April Barnado2, 1Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Antimalarials (AMs) improve survival in patients with systemic lupus erythematosus (SLE). Current guidelines suggest AMs for all SLE nephritis patients. Studies using patient-reported data…
  • Abstract Number: 2647 • 2018 ACR/ARHP Annual Meeting

    Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data

    Manish Rathi1, Aman Sharma2, Joyita Sharma3 and Krishan L Gupta3, 1Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, 3Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarrh, India

    Background/Purpose: We present the long-term follow-up of patients with lupus nephritis who completed the randomized controlled trial on comparison of low-dose intravenous cyclophosphamide (IV CYC)…
  • « Previous Page
  • 1
  • …
  • 1178
  • 1179
  • 1180
  • 1181
  • 1182
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology